(Axios) – There’s an emerging debate around a popular class of anti-obesity drugs: whether patients who go on themcan ever expect to stop taking them. Why it matters: The drugs represent an important shift in treating obesity as a chronic disease, but that has costly implications. Much of the tension around the drugs’ long-term use is being driven by the insurers paying for them and clinicians who prescribe them. (Read More)